2. Search Result
Search Result
Results for "

Osteosarcoma Inhibitor

" in MedChemExpress (MCE) Product Catalog:

87

Inhibitors & Agonists

2

Fluorescent Dye

2

Biochemical Assay Reagents

4

Peptides

3

Inhibitory Antibodies

24

Natural
Products

3

Isotope-Labeled Compounds

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12238
    IWR-1
    Maximum Cited Publications
    61 Publications Verification

    endo-IWR 1; IWR-1-endo

    		 Organoid Wnt Inflammation/Immunology Cancer
    IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis .
    IWR-1
  • HY-N0153
    Naringin
    Maximum Cited Publications
    24 Publications Verification

    Naringoside

    		 Cytochrome P450 Autophagy Mitophagy Endogenous Metabolite Inflammation/Immunology Cancer
    Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities. Naringin also inhibits proliferation and invasion and induces apoptosis in human osteosarcoma cells by inhibiting zinc finger E-box binding homeobox 1 (Zeb1) .
    Naringin
  • HY-N0484
    Liensinine
    15+ Cited Publications

    		 Reactive Oxygen Species (ROS) Autophagy Apoptosis VEGFR JAK Amyloid-β p38 MAPK HIF/HIF Prolyl-Hydroxylase STAT PI3K JNK Akt Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Liensinine is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .
    Liensinine
  • HY-134901
    WM-3835
    5+ Cited Publications

    		 Histone Acetyltransferase Apoptosis Cancer
    WM-3835 is a potent and high-specific HBO1 (KAT7 or MYST2) inhibitor and binds directly to the acetyl-CoA binding site of HBO1. WM-3835 activates apoptosis while inhibits osteosarcoma (OS) cell proliferation, migration and invasion. WM-3835 has antitumor activity and potently inhibits pOS-1 xenograft growth in mice .
    WM-3835
  • HY-17372
    Rofecoxib
    5 Publications Verification

    MK 966

    		 COX Inflammation/Immunology Cancer
    Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells).
    Rofecoxib
  • HY-124586
    Streptonigrin
    1 Publications Verification

    Bruneomycin

    		 Antibiotic Protein Arginine Deiminase E1/E2/E3 Enzyme HIF/HIF Prolyl-Hydroxylase MDM-2/p53 Apoptosis Infection Inflammation/Immunology Cancer
    Streptonigrin (Bruneomycin) is an orally active antibiotic and pan-PAD inhibitor, inhibiting PAD1, PAD2, PAD3 and PAD4 with IC50 of 48.3 μM, 26.1 μM, 0.43 μM and 2.5 μM, respectively. Streptonigrin inhibits SENP1 (IC50 of 0.518 μM) and reduces HIF1α. Streptonigrin increases p53 and Apoptosis. Streptonigrin shows antiviral activity against Rauscher murine leukemia virus. Streptonigrin has immunosuppressive effects. Streptonigrin has antitumor activity against osteosarcoma .
    Streptonigrin
  • HY-164561
    TASIN-30
    1 Publications Verification

    		 Emopamil Binding Protein Ferroptosis Apoptosis Cancer
    TASIN-30 is a selective EBP inhibitor with an EC50 of 0.097 μM. TASIN-30 blocks the production of 7-dehydrocholesterol (7-DHC) and downstream cholesterol biosynthesis processes. TASIN-30 depletes downstream sterols, disrupts the integrity of lipid rafts in tumor cells, accelerates intracellular cholesterol consumption, and inhibits tumor cell proliferation. TASIN-30 induces ferroptosis and apoptosis by reducing 7-DHC levels and increasing phospholipid peroxidation. TASIN-30 achieves tumor suppression in nude mice with osteosarcoma. TASIN-30 can be used in cancer-related research such as colorectal cancer and osteosarcoma .
    TASIN-30
  • HY-127009
    Levoleucovorin

    Levofolinic acid; Levofolene

    		 Lysyl Oxidase Apoptosis Metabolic Disease Cancer
    Levoleucovorin (Levofolinic acid; Levofolene) is the pharmacologically and orally active levoisomer of Folinic acid (HY-17556), a synthetic folate analogue. Levoleucovorin can inhibit LOXL2 with an IC50 of 68.81 μM. Levoleucovorin can inhibit cancer cells proliferation, migration and induce apoptosis. Levoleucovorin can be used as a rescue agent for high-dose Methotrexate (HY-14519). Levoleucovorin can reduce the frequency of embryonic malformations. Levoleucovorin can be used for the research of can and endocrinology, such as breast cancer and osteosarcoma .
    Levoleucovorin
  • HY-N0837
    Veratramine
    1 Publications Verification

    NSC17821; NSC23880

    		 PI3K Akt mTOR Autophagy Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy .
    Veratramine
  • HY-N0563
    Alizarin
    1 Publications Verification

    		 AMPK VEGFR PI3K Akt NF-κB Cytochrome P450 Cardiovascular Disease Cancer
    Alizarin is a natural dye. Alizarin can be extracted from the roots of madder plant. Alizarin activates AMPK and VEGFR2/eNOS pathway. Alizarin regulates PI3K/Akt and inhibits NF-κB pathway. Alizarin enhances CYP1A1 enzyme activity. Alizarin has protective effects on hypertension and vascular endothelial dysfunction. Alizarin has anti-tumor activity against multiple cancers including pancreatic cancer, breast cancer, osteosarcoma and liver cancer. Alizarin has been widely used as a pigment in textile fabrics and paintings .
    Alizarin
  • HY-163573
    FANCM-BTR PPI-IN-1

    		DNA/RNA Synthesis Cancer
    FANCM-BTR PPI-IN-1 (Compound 32) is a FANCM/BTR interaction inhibitor that blocks the localization of FANCM to telomeres. FANCM-BTR PPI-IN-1 exhibits anticancer activity against osteosarcoma .
    FANCM-BTR PPI-IN-1
  • HY-151500
    JBSNF-000028 free base

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 free base is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 free base can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 free base exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 free base can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 free base
  • HY-B0012
    Pamidronic acid
    1 Publications Verification

    		 RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin Metabolic Disease Inflammation/Immunology Cancer
    Pamidronic acid, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronic acid significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of OPG in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronic acid can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .
    Pamidronic acid
  • HY-N7135
    Tropolone

    		Tyrosinase Fungal Metabolic Disease Inflammation/Immunology Cancer
    Tropolone is a seven-membered non-benzenoid aromatic compound, which is the precursor of many Azulene derivatives. Tropolone is a potent mushroom tyrosinase inhibitor with an IC50 value of 0.4 μM. Its inhibitory effect can be achieved by dialysis or excess CU2+ Reversa. Tropolone exhibits broad anti-viral and anti-fungal activity and is synergistic upon co-treatment with nucleos(t)ide analog drugs. Tropolone is a promising candidate for research in osteosarcoma .
    Tropolone
  • HY-N3387
    Licoricidin

    		Apoptosis NF-κB Akt MMP Inflammation/Immunology Cancer
    Licoricidin (LCD) is isolated from Glycyrrhiza uralensis Fisch, possesses anti-cancer activities. Licoricidin (LCD) inhibit SW480 cells (IC50=7.2 μM) by inducing cycle arrest, apoptosis and autophagy, and is a potential chemopreventive or chemotherapeutic agent against colorectal cancer . Licoricidin (LCD) inhibits Lung Metastasis by inhibition of tumor angiogenesis and lymphangiogenesis as well as changes in the local microenvironment of tumor tissues the anticarcinogenic effect . Licoricidin enhanced gemcitabine-induced cytotoxicity in Osteosarcoma (OS) cells by inactivation of the Akt and NF-κB pathways in vitro and in vivo . Licoricidin blocks UVA-induced photoaging via ROS scavenging, limits the activity of MMP-1, it can be considered as an active ingredient in new topically applied anti-ageing formulations .
    Licoricidin
  • HY-N0819
    Raddeanin A
    1 Publications Verification

    		 Apoptosis PI3K Akt ERK mTOR Wnt β-catenin Wee1 JNK VEGFR CDK Neurological Disease Inflammation/Immunology Cancer
    Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma .
    Raddeanin A
  • HY-N2112
    Glaucocalyxin A
    2 Publications Verification

    		 PI3K Akt Apoptosis Cancer
    Glaucocalyxin A, an ent-kauranoid diterpene from Rabdosia japonica var., induces apoptosis in osteosarcoma by inhibiting nuclear translocation of Five-zinc finger Glis 1 (GLI1) via regulating PI3K/Akt signaling pathway. Glaucocalyxin A has antitumor effect .
    Glaucocalyxin A
  • HY-B0012A
    Pamidronate disodium
    1 Publications Verification

    CGP 23339A

    		 RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin Metabolic Disease Inflammation/Immunology Cancer
    Pamidronate disodium (CGP 23339A), the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of osteoprotegerin in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .
    Pamidronate disodium
  • HY-B0730
    Pamidronate disodium pentahydrate
    1 Publications Verification

    		 RANKL/RANK Toll-like Receptor (TLR) Wnt β-catenin Metabolic Disease Inflammation/Immunology Cancer
    Pamidronate disodium pentahydrate, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium pentahydrate significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of osteoprotegerin in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium pentahydrate can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma .
    Pamidronate disodium pentahydrate
  • HY-N2896
    Arjunolic acid

    		Reactive Oxygen Species (ROS) Apoptosis Fungal Bacterial NF-κB SOD AMPK mTOR Notch Toll-like Receptor (TLR) Wnt MyD88 Sirtuin Infection Neurological Disease Inflammation/Immunology Cancer
    Arjunolic acid is an orally active, multifunctional bioactive compound. Arjunolic acid exhibits free radical scavenging activity, as well as fungal and bacterial activities. Arjunolic acid induces apoptosis (Apoptosis) in various cancer cells. Arjunolic acid protects hepatocytes against induced oxidative stress and apoptosis by reducing reactive oxygen species and inhibiting NF-κB activation. Arjunolic acid regulates pancreatic dysfunction in type 2 diabetic rats by blocking the activation of the TLR-4/MyD88 and canonical Wnt pathways. Arjunolic acid inhibits neuroinflammation and ameliorates depressive behaviors via the SIRT1/AMPK/Notch1 signaling pathway in microglia. Arjunolic acid improves Crohn's disease-like colitis by restoring gut microbiota composition and inhibiting TLR4 signaling. Arjunolic acid suppresses osteosarcoma progression by inhibiting Wnt3a-mediated M2 polarization of macrophages. Arjunolic acid ameliorates diabetic retinopathy via the autophagy pathway regulated by AMPK/mTOR/HO-1. Arjunolic acid is applicable to research related to type 2 diabetes, organ toxicity, depression, Crohn's disease, osteosarcoma, diabetic retinopathy, and testicular dysfunction .
    Arjunolic acid
  • HY-158109
    M3554

    		Antibody-Drug Conjugates (ADCs) CD2 Topoisomerase Cancer
    M3554 is an anti-GD2 antibody-drug conjugate (ADC) based on the humanized anti-GD2 antibody. M3554 consists of the humanized monoclonal antibody hu14.18 (K322A) (HY-P991040) linked to a topoisomerase 1 inhibitor Exatecan (HY-13631) via a cleavable β-glucuronide linker. M3554 can be used for the study of neuroblastoma, osteosarcoma or glioma .
    M3554
  • HY-P990858
    Anti-CD47 Antibody (B6.H12)

    		CD47 Cancer
    Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47 Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47 Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47 Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47 Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma .
    Anti-CD47 Antibody (B6.H12)
  • HY-169053
    SU1261

    		IKK NF-κB Cancer
    SU1261 is an IKK inhibitor with Ki values of 10 nM and 680 nM for IKKα and IKKβ, respectively. SU1261 can inhibit non-canonical NF-κB signaling in U2OS osteosarcoma cells .
    SU1261
  • HY-151500B
    JBSNF-000028 hydrochloride

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 hydrochloride is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 hydrochloride can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 hydrochloride exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 hydrochloride can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 hydrochloride
  • HY-122714
    SK-216

    		PAI-1 Cancer
    SK-216 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor that acts as an anti-metastatic agent for human osteosarcoma and inhibits lung metastasis of human osteosarcoma .
    SK-216
  • HY-148099
    USP1-IN-2

    		Deubiquitinase Cancer
    USP1-IN-2 (Compound I-193) is a potent ubiquitin-specific protease 1 (USP1) inhibitor with an IC50 of less than about 50 nM. USP1-IN-2 can be used for the study of cancers such as osteosarcoma .
    USP1-IN-2
  • HY-171656
    G721-0282

    		Glycosidase NF-κB COX STAT ERK p38 MAPK Apoptosis CDK Survivin Bcl-2 Family Neurological Disease Inflammation/Immunology Cancer
    G721-0282 is an orally active CHI3L1 inhibitor. G721-0282 can reduce the expression of inflammatory proteins and cytokines. G721-0282 inhibits the activation of the NF-κB signaling pathway. G721-0282 inhibits neuroinflammation and reduces anxious behavior. G721-0282 significantly inhibits the proliferation of osteosarcoma (OS) cells by suppressing the STAT3 signaling pathway. G721-0282 induces OS cell apoptosis by upregulating pro-apoptotic protein levels and downregulating anti-apoptotic protein levels. G721-0282 can be used for researches on neuroinflammatory conditions and cancer .
    G721-0282
  • HY-174996
    NEP162

    		PROTACs Epigenetic Reader Domain Apoptosis Cancer
    NEP162 is a BRD4 PROTAC degrader with DC50s of 1.2 and 1.6 μM in SW480 and U2OS cells. NEP162 exhibits antiproliferative activity, effectively inhibits tumor growth and induces apoptosis. NEP162 can be used for the study of osteosarcoma, colorectal cancer and non-small cell lung cancer, etc. (Pink: BRD4 ligand : (HY-78695), Blue: E3 ligase Ligand (HY-D2259), BLACK: Linker, E3 ligase ligand-linker conjugate (HY-174997)) .
    NEP162
  • HY-N0885
    Telocinobufagin
    1 Publications Verification

    Telobufotoxin; Telocinobufogenin

    		 JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and PLK1 pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na +/K +-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models .
    Telocinobufagin
  • HY-119715
    AG-012986

    		CDK Apoptosis Inflammation/Immunology Cancer
    AG-012986 is a pan-CDK inhibitor with Ki values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces Ki-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .
    AG-012986
  • HY-N7385
    Nudol

    		MMP Apoptosis Cancer
    Nudol is a phenanthrene compound that has anti-cancer activity. Nudol inhibits cell proliferation, induces cell apoptosis. Nudol inhibits MMP-2M and MMP-9 activity (Ki: 988.9 nM, 1.76 μM, respectively). Nudol can be used in the research of cancers, such as osteosarcoma .
    Nudol
  • HY-N6611
    Chimaphilin

    		IGF-1R Infection Inflammation/Immunology Cancer
    Chimaphilin is an IGF-1R inhibitor (IC50: 0.086 μM). Chimaphilin has antifungal, antioxidant and anticancer activities. Chimaphilin inhibits the growth of both drug-sensitive and drug-resistant osteosarcoma cell lines. Chimaphilin can induce cancer cell apoptosis. Chimaphilin is a main component of pyrola .
    Chimaphilin
  • HY-N0153R
    Naringin (Standard)
    Maximum Cited Publications
    24 Publications Verification

    Naringoside (Standard)

    		 Endogenous Metabolite Cytochrome P450 Mitophagy Autophagy Reference Standards Inflammation/Immunology Cancer
    Naringin is a major flavanone glycoside obtained from tomatoes, grapefruits, and many other citrus fruits. Naringin exhibits biological properties such as antioxidant, anti-inflammatory, and antiapoptotic activities. Naringin also inhibits proliferation and invasion and induces apoptosis in human osteosarcoma cells by inhibiting zinc finger E-box binding homeobox 1 (Zeb1) .
    Naringin (Standard)
  • HY-W020958
    Ru(acac)3

    Tris(acetylacetonato)ruthenium (III)

    		 Caspase Apoptosis Cancer
    Ru (acac) 3 (Tris (acetylacetonato) ruthenium (III)) is a caspase-3 activator and Apoptosis inducer. Ru (acac) 3 exerts growth inhibitory effects on various cell lines in vitro by inhibiting DNA/RNA synthesis and inducing mild reversible S-phase cell cycle arrest. Ru (acac) 3 is commonly used in research related to ovarian cancer, osteosarcoma, cervical cancer, melanoma, and other fields .
    Ru(acac)3
  • HY-N6932
    Voacamine

    		Cannabinoid Receptor P-glycoprotein PI3K Akt mTOR Apoptosis Autophagy EGFR Metabolic Disease Cancer
    Voacamine is an indole alkaloid with cannabinoid 1 (CB1) antagonistic activity. Voacamine can inhibit nuclear translocation. Voacamine is effective in enhancing the effect of Doxorubicin (HY-15142A) as it interferes with the P-glycoprotein (P-gp) function. Voacamine promotes apoptosis-independent autophagic cell death in human osteosarcoma cells. Voacamine activates mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway to suppress breast cancer progression. Voacamine inhibits EGFR to exert oncogenic activity against colorectal cancer .
    Voacamine
  • HY-169296
    IMPDH2-IN-4

    		IMPDH Cancer
    IMPDH2-IN-4 (Compound 2d) is a selective IMPDH2 inhibitor with a Ki,app value of 1.8 μM. IMPDH2-IN-4 exhibits anti-cancer activity against osteosarcoma. IMPDH2-IN-4 can be used in research related to osteosarcoma .
    IMPDH2-IN-4
  • HY-P3730
    Cdk2/Cyclin Inhibitory Peptide I

    		CDK Cancer
    Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG), a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner .
    Cdk2/Cyclin Inhibitory Peptide I
  • HY-N6865
    Groenlandicine
    2 Publications Verification

    		 Cholinesterase (ChE) Topoisomerase Reactive Oxygen Species (ROS) Beta-secretase Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Groenlandicine, a protoberberine alkaloid, is a cholinesterase inhibitor (AChE (IC50 = 0.54 μM), BChE (IC50 = 3.32 μM)). Groenlandicine non-competitively inhibits BACE1 (IC50 = 19.68 μM, Ki = 21.2) and inhibits RLAR (IC50 = 140.1 μM), HRAR (IC50 = 154.2 μM), and total ROS generation (IC50 = 51.78 μM) in vitro. Groenlandicine suppresses osteosarcoma cell proliferation while promoting apoptosis. Groenlandicine inhibits the tumor growth when combined with Cisplatin (HY-17394). Groenlandicine can be used for the study on osteosarcoma, Alzheimer's disease and diabetes mellitus .
    Groenlandicine
  • HY-17509
    Deracoxib
    1 Publications Verification

    SC 046; SC 46; SC 59046

    		 COX Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Deracoxib (SC 046; SC 59046), an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas .
    Deracoxib
  • HY-151500A
    JBSNF-000028 TFA

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 TFA is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 TFA can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 TFA exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 TFA can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028 TFA
  • HY-N0837R
    Veratramine (Standard)

    NSC17821 (Standard); NSC23880 (Standard)

    		 Reference Standards PI3K Akt mTOR Autophagy Apoptosis Neurological Disease Metabolic Disease Cancer
    Veratramine (NSC17821; NSC23880) (Standard) is the analytical standard of Veratramine (HY-N0837). This product is intended for research and analytical applications. Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy .
    Veratramine (Standard)
  • HY-178989
    PGK1-IN-2

    		Phosphoglycerate Kinase (PGK) Cuproptosis Cancer
    PGK1-IN-2 (Compound 60) is a PGK1 inhibitor with an IC50 of 8.24 μM. PGK1-IN-2 demonstrates a significant ability to inhibit the proliferation of osteosarcoma cells. PGK1-IN-2 interferes with the glycolytic pathway of tumor cells by inhibiting PGK1. PGK1-IN-2 inhibits cell migration and invasion, and induces cell S phase and G2-M phase cycle arrest. PGK1-IN-2 may kill cells by inducing cuproptosis. PGK1-IN-2 shows a significant anti-tumor effect in the MNNG-HOS osteosarcoma xenograft mouse model. PGK1-IN-2 can be used for the study of osteosarcoma .
    PGK1-IN-2
  • HY-176261
    DDD2

    		PROTACs Cancer
    DDD2 is a selective and potent VHL-mediated PROTAC NUDT5 degrader. DDD2 induces robust NUDT5 degradation. DDD2 can be used in cancer research, such as lymphocytic leukemia and osteosarcoma . (Structure Note: Pink: NUDT5 inhibitor (HY-176262); Blue: E3 (HY-125845); Black: linker (HY-W001958))
    DDD2
  • HY-17509S
    Deracoxib-d3

    SC 046-d3; SC 46-d3; SC 59046-d3

    		 Isotope-Labeled Compounds COX Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Deracoxib-d3 (SC 046-d3; SC 59046-d3) is the deuterium labeled Deracoxib (HY-17509). Deracoxib, an orally active COX-2 inhibitor, is a veterinary nonsteroidal anti-inflammatory agent used exclusively in dogs. Deracoxib inhibits the COX-2 enzyme to reduce the production of prostaglandins, effectively controlling pain and inflammation after canine soft tissue surgery. Deracoxib reduces the inhibition of COX-1 and lowers the risk of gastrointestinal side effects. Deracoxib induces tumor cell cycle arrest and apoptosis, and shows anti-tumor activity in canine osteosarcoma, breast tumors and bladder transitional cell carcinomas.
    Deracoxib-d3
  • HY-151500C
    JBSNF-000028

    		Amine N-methyltransferase Metabolic Disease
    JBSNF-00002 is an orally active small molecule inhibitor of the tricyclic nicotinamide N-methyltransferase (NNMT) with IC50 values for human, mouse and monkey sources of NNMT of 33, 210 and 190 nM respectively. JBSNF-00002 can reduce endogenous MNA levels in U2OS osteosarcoma cells, with its EC50 being 2.5 μM. JBSNF-00002 exhibits significant anti-obesity and anti-diabetic activities in the diet-induced obesity (DIO) model. JBSNF-00002 can be used for the study of metabolic diseases such as obesity, type 2 diabetes and non-alcoholic fatty liver disease .
    JBSNF-000028
  • HY-N5014
    Liensinine perchlorate
    15+ Cited Publications

    		 Reactive Oxygen Species (ROS) Autophagy Apoptosis VEGFR JAK Amyloid-β p38 MAPK HIF/HIF Prolyl-Hydroxylase STAT PI3K JNK Akt Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Liensinine perchlorate is a bisbenzylisoquinoline alkaloid. By inhibiting the PI3K/AKT and JNK/p38-MAPK signaling pathways, Liensinine perchlorate suppresses autophagy and apoptosis, clears Aβ, and exerts anti-inflammatory, antioxidant and neuroprotective effects. Liensinine perchlorate activates AMPK and inhibits the expression of HIF-1α and VEGF, thereby suppressing angiogenesis. Liensinine perchlorate exerts anti-tumor effects through ROS-mediated inhibition of the JAK2/STAT3 signaling pathway. Liensinine perchlorate can be used for the research of diseases such as Alzheimer's disease, hepatocellular carcinoma, osteosarcoma, sepsis-induced organ injury and stroke .
    Liensinine perchlorate
  • HY-162970
    XD23

    		Wnt Cancer
    XD23 is a potent osteosarcoma inhibitor that works by downregulating DKK1 and activating the WNT/β-catenin signaling pathway.
    XD23
  • HY-123369
    BMI-1026

    		CDK Apoptosis Cancer
    BMI-1026 is a cyclin-dependent kinase 1 (Cdk1) inhibitor with IC50 of 2.3 nM. BMI-1026 induces apoptosis by arresting the G2-M phase .
    BMI-1026
  • HY-13752
    STA-1474

    		HSP Cancer
    STA-1474 is an orally active and highly selective HSP90 inhibitor. STA-1474 can trigger tumor cell apoptosis. STA-1474 demonstrates significant antitumor efficacy in spontaneous canine cancer models (e.g., osteosarcoma, thyroid carcinoma). STA-1474 is promising for research of solid tumors (e.g., osteosarcoma, breast cancer) and HSP90-driven cancers .
    STA-1474
  • HY-12941
    AM-7209

    		MDM-2/p53 Cancer
    AM-7209 is a potent and selective MDM2-p53 interaction inhibitor with a Kd of 38 pM. AM-7209 inhibits the MDM2 amplified SJSA-1 osteosarcoma cell line with an IC50 of 1.6 nM. AM-7209 shows antitumor activities .
    AM-7209

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: